Literature DB >> 8948420

Treatment options for localized recurrence of prostate cancer following radiation therapy.

D A Corral1, L L Pisters, A C von Eschenbach.   

Abstract

Patients with radioresistant clinically localized prostate cancer may be treated by various means. Although androgen ablation is relatively noninvasive, it cannot be considered a curative option. We believe that a subset of patients with locally recurrent prostate cancer without subclinical metastatic disease exists and would benefit from maximally aggressive local therapy. Salvage surgery may offer long-term cancer control, particularly when the tumor is organ-confined, but is a technically challenging operation with a high incidence of postoperative incontinence. Cryoablation of the prostate for postirradiation recurrence may offer a less invasive alternative to radical surgery, but its long-term efficacy remains to be fully determined. Each therapeutic option has its characteristic attendant morbidity and the choice of therapy for local recurrence should be made with informed consent after frank discussion between physician and patient. We propose the treatment algorithm shown in Figure 1 for the management of patients with suspected recurrence after radiation therapy with the caveat that individual therapeutic strategies must be patterned around individual patient needs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8948420     DOI: 10.1016/s0094-0143(05)70345-1

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  2 in total

Review 1.  Prostate cancer: 11. Alternative approaches and the future of treatment.

Authors:  J Trachtenberg; J Crook; I F Tannock
Journal:  CMAJ       Date:  1999-02-23       Impact factor: 8.262

2.  Exposure to hyperbaric oxygen induces cell cycle perturbation in prostate cancer cells.

Authors:  J E Kalns; E H Piepmeier
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-02       Impact factor: 2.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.